ALTANT EVAC project

Project partners UMC Utrecht, Utrecht University and MSD Animal Health


‘New approach to vaccine development: targeting evasion molecules.'

Introduction to the project

Evasion molecules in staphylococcal bovine mastitis vaccines (EVAC) is exploring a new approach to vaccine development: Targeting evasion molecules.

Evasion molecules are shed by bacteria in order to mislead or even inhibit the host’s immune system, thus avoiding clearance by the host. By teaching the immune system to target such evasion molecules, e.g. by specific vaccination protocols, the immune system may be able to recognize and attack the pathogen.

Project leader Jos van Strijp is professor at University Medical Center Utrecht (UMCU) and director of Infection and Immunity Center Utrecht. In EVAC he works together with Utrecht University and MSD Animal Health. “We are in constant interaction with MSD and they are testing our results in cows. This is an effective testing method that we could not have utilized without them.”, says van Strijp. Paul Vermeij, Head Discovery & Technology-Research at MSD Animal Health:” The partnership in EVAC works, since we both bring added value to the project and respect each other’s interests. In this setting collaboration between animal health and human health research groups can be effective.”

According to van Strijp, this project with MSD is a good example of public private partnership, proving the value of Immuno Valley and the One Health approach. “The One Health approach is one of our priorities for the coming years. Immuno Valley makes it possible to initiate large partnerships with multiple organizations in this field.” 

Project Aim 

EVAC aims to develop a new staphylococcal bovine mastitis vaccine for both man and animals.

Facts & Figures

Partners: University Medical Center Utrecht (UMCU), Utrecht University; MSD Animal Health.